The importance of non-HLA antibodies in transplantation

Nature Reviews Nephrology

Volumn 12, Issue 8, 2016, Pages 484-495

  Zhang, Qiuheng ^a   Reed, Elaine F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIGEN; AUTOANTIBODY; AUTOANTIGEN; COLLAGEN; HLA ANTIBODY; PERLECAN; PROTEOHEPARAN SULFATE;

ALLOIMMUNITY; ANTIBODY PRODUCTION; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELL MATURATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); EXOSOME; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; KIDNEY TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHOID TISSUE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SURGICAL INJURY; TH17 CELL; HISTOCOMPATIBILITY; IMMUNOLOGY;

AUTOANTIBODIES; AUTOANTIGENS; COLLAGEN; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; KIDNEY TRANSPLANTATION; RECEPTOR, ANGIOTENSIN, TYPE 1; TRANSPLANTATION IMMUNOLOGY;

EID: 84976321269     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2016.88     Document Type: Review

References (152)

1. Stegall, M. D. et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am. J. Transplant. 11, 2405-2413 (2011).
2. Amico, P. et al. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 87, 1681-1688 (2009).
3. Gloor, J. M. et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am. J. Transplant. 10, 582-589 (2010).
4. Everly, M. J. Incidence and hazards of alloantibodies in renal transplantation. Clin. Transpl. 313-317 (2013).
5. Wiebe, C. et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am. J. Transplant. 12, 1157-1167 (2012).
6. Lefaucheur, C. et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J. Am. Soc. Nephrol. 21, 1398-1406 (2010).
7. Gourishankar, S. et al. Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study. Am. J. Transplant. 10, 324-330 (2010).
8. Grafft, C. A. et al. Antibody-mediated rejection following transplantation from an HLA-identical sibling. Nephrol. Dial. Transplant. 25, 307-310 (2010).
9. Kalil, J. et al. Humoral rejection in two HLA identical living related donor kidney transplants. Transplant. Proc. 21, 711-713 (1989).
10. Montoliu, J. et al. Delayed hyperacute rejection in recipients of kidney transplants from HLA identical sibling donors. Am. J. Med. 67, 590-596 (1979).
11. Terasaki, P. I. Deduction of the fraction of immunologic and non-immunologic failure in cadaver donor transplants. Clin. Transpl. 449-452 (2003).
12. Opelz, G. & Collaborative Transplant Study. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 365, 1570-1576 (2005).
13. Bordron, A. et al. Functional heterogeneity of anti-endothelial cell antibodies. Clin. Exp. Immunol. 124, 492-501 (2001).
14. Zou, Y., Stastny, P., Susal, C., Dohler, B. & Opelz, G. Antibodies against MICA antigens and kidney-transplant rejection. N. Engl. J. Med. 357, 1293-1300 (2007).
15. Brasile, L., Rodman, E., Shield, C. F. III, Clarke, J. & Cerilli, J. The association of antivascular endothelial cell antibody with hyperacute rejection: a case report. Surgery 99, 637-640 (1986).
16. Harmer, A. W., Haskard, D., Koffman, C. G. & Welsh, K. I. Novel antibodies associated with unexplained loss of renal allografts. Transpl. Int. 3, 66-69 (1990).
17. Jackson, A. M., Kuperman, M. B. & Montgomery, R. A. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am. J. Transplant. 12, 1643-1649 (2012).
18. Jordan, S. C., Yap, H. K., Sakai, R. S., Alfonso, P. & Fitchman, M. Hyperacute allograft rejection mediated by anti-vascular endothelial cell antibodies with a negative monocyte crossmatch. Transplantation 46, 585-587 (1988).
19. Niikura, T. et al. Probable C4d-negative accelerated acute antibody-mediated rejection due to non-HLA antibodies. Nephrology (Carlton) 20 (Suppl. 2), 75-78 (2015).
20. Sumitran-Karuppan, S., Tyden, G., Reinholt, F., Berg, U. & Moller, E. Hyperacute rejections of two consecutive renal allografts and early loss of the third transplant caused by non-HLA antibodies specific for endothelial cells. Transpl. Immunol. 5, 321-327 (1997).
21. Perrey, C., Brenchley, P. E., Johnson, R. W. & Martin, S. An association between antibodies specific for endothelial cells and renal transplant failure. Transpl. Immunol. 6, 101-106 (1998).
22. Le Bas-Bernardet, S. et al. Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am. J. Transplant. 3, 167-177 (2003).
23. Zhang, Q. et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 91, 1153-1158 (2011).
24. Breimer, M. E. et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 87, 549-556 (2009).
25. Daniel, V. et al. Clinical relevance of preformed IgG and IgM antibodies against donor endothelial progenitor cells in recipients of living donor kidney grafts. Clin. Transplant. 30, 124-130 (2016).
26. Sun, Q. et al. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Transplantation 79, 1759-1762 (2005).
27. Mahesh, B. et al. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am. J. Pathol. 170, 1415-1427 (2007).
28. Mahesh, B. et al. Autoimmunity to vimentin potentiates graft vasculopathy in murine cardiac allografts. Transplantation 90, 4-13 (2010).
29. Fuss, A. et al. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies. Nephrology (Carlton) 20, 467-473 (2015).
30. Reinsmoen, N. L. et al. Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 90, 1473-1477 (2010).
31. Jackson, A. M., Lucas, D. P., Melancon, J. K. & Desai, N. M. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation 92, 54-60 (2011).
32. Pearl, M. H. et al. Accelerated rejection, thrombosis, and graft failure with angiotensin II type 1 receptor antibodies. Pediatr. Nephrol. 30, 1371-1374 (2015).
33. Dragun, D. et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 352, 558-569 (2005).
34. Li, L. et al. Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proc. Natl Acad. Sci. USA 106, 4148-4153 (2009).
35. Sigdel, T. K. et al. Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J. Am. Soc. Nephrol. 23, 750-763 (2012).
36. Jackson, A. M. et al. Endothelial cell antibodies associated with novel targets and increased rejection. J. Am. Soc. Nephrol. 26, 1161-1171 (2015).
37. Seva Pessoa, B. et al. Key developments in renin-angiotensin-aldosterone system inhibition. Nat. Rev. Nephrol. 9, 26-36 (2013).
38. Xia, Y. & Kellems, R. E. Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond. Circ. Res. 113, 78-87 (2013).
39. Wallukat, G. et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J. Clin. Invest. 103, 945-952 (1999).
40. Giral, M. et al. Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss. Am. J. Transplant. 13, 2567-2576 (2013).
41. In, J. W. et al. Anti-angiotensin type 1 receptor antibodies associated with antibody-mediated rejection in patients without preformed HLA-donor-specific antibody. Transplant. Proc. 46, 3371-3374 (2014).
42. Lee, J. et al. The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation. Nephrol. Dial. Transplant. http://dx.doi.org/10.1093/ndt/gfv375 (2015).
43. Lee, J. et al. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation. Transplant. Proc. 47, 649-652 (2015).
44. Taniguchi, M. et al. Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies. Am. J. Transplant. 13, 2577-2589 (2013).
45. Hesemann, L. E., Subramanian, V., Mohanakumar, T. & Dharnidharka, V. R. De novo development of antibodies to kidney-associated self-antigens angiotensin II receptor type I, collagen IV, and fibronectin occurs at early time points after kidney transplantation in children. Pediatr. Transplant. 19, 499-503 (2015).
46. Banasik, M. et al. Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss. Transplant. Proc. 46, 2618-2621 (2014).
47. Cravedi, P., Kopp, J. B. & Remuzzi, G. Recent progress in the pathophysiology and treatment of FSGS recurrence. Am. J. Transplant. 13, 266-274 (2013).
48. Abbott, K. C. et al. Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States. Am. J. Kidney Dis. 37, 366-373 (2001).
49. Vincenti, F. & Ghiggeri, G. M. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am. J. Transplant. 5, 1179-1185 (2005).
50. Choy, B. Y., Chan, T. M. & Lai, K. N. Recurrent glomerulonephritis after kidney transplantation. Am. J. Transplant. 6, 2535-2542 (2006).
51. Hoffmann, S., Podlich, D., Hahnel, B., Kriz, W. & Gretz, N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J. Am. Soc. Nephrol. 15, 1475-1487 (2004).
52. Alachkar, N., Gupta, G. & Montgomery, R. A. Angiotensin antibodies and focal segmental glomerulosclerosis. N. Engl. J. Med. 368, 971-973 (2013).
53. Mujtaba, M. A. et al. Pre-transplant angiotensin receptor II type 1 antibodies and risk of post-transplant focal segmental glomerulosclerosis recurrence. Clin. Transplant. 29, 606-611 (2015).
54. Delville, M. et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci. Transl Med. 6, 256ra136 (2014).
55. Hiemann, N. E. et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 94, 919-924 (2012).
56. Reinsmoen, N. L. et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation 97, 595-601 (2014).
57. Urban, M. et al. The impact of angiotensin II type 1 receptor antibodies on post-heart transplantation outcome in Heart Mate II bridged recipients. Interact. Cardiovasc. Thorac. Surg. 22, 292-297 (2016).
58. Fillion, D. et al. Structure of the human angiotensin II type 1 (AT1) receptor bound to angiotensin II from multiple chemoselective photoprobe contacts reveals a unique peptide binding mode. J. Biol. Chem. 288, 8187-8197 (2013).
59. Unal, H., Jagannathan, R., Bhat, M. B. & Karnik, S. S. Ligand-specific conformation of extracellular loop-2 in the angiotensin II type 1 receptor. J. Biol. Chem. 285, 16341-16350 (2010).
60. Unal, H. et al. Long range effect of mutations on specific conformational changes in the extracellular loop 2 of angiotensin II type 1 receptor. J. Biol. Chem. 288, 540-551 (2013).
61. Wang, W. et al. Stimulatory activity of anti-peptide antibodies against the second extracellular loop of human M2 muscarinic receptors. Chin. Med. J. (Engl.) 113, 867-871 (2000).
62. Lebesgue, D. et al. An agonist-like monoclonal antibody against the human β2-adrenoceptor. Eur. J. Pharmacol. 348, 123-133 (1998).
63. Unal, H., Jagannathan, R. & Karnik, S. S. Mechanism of GPCR-directed autoantibodies in diseases. Adv. Exp. Med. Biol. 749, 187-199 (2012).
64. Zhang, S. et al. Angiotensin type 1 receptor autoantibody from preeclamptic patients induces human fetoplacental vasoconstriction. J. Cell. Physiol. 228, 142-148 (2013).
65. Lukitsch, I. et al. Renal ischemia and transplantation predispose to vascular constriction mediated by angiotensin II type 1 receptor-activating antibodies. Transplantation 94, 8-13 (2012).
66. Ehrenstein, M. R. & Notley, C. A. The importance of natural IgM: scavenger, protector and regulator. Nat. Rev. Immunol. 10, 778-786 (2010).
67. Zhang, M. et al. The role of natural IgM in myocardial ischemia-reperfusion injury. J. Mol. Cell Cardiol. 41, 62-67 (2006).
68. Iozzo, R. V. & Sanderson, R. D. Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J. Cell. Mol. Med. 15, 1013-1031 (2011).
69. Cailhier, J. F. et al. Caspase-3 activation triggers extracellular cathepsin L release and endorepellin proteolysis. J. Biol. Chem. 283, 27220-27229 (2008).
70. Cardinal, H. et al. Antiperlecan antibodies are novel accelerators of immune-mediated vascular injury. Am. J. Transplant. 13, 861-874 (2013).
71. O'Riordan, E., Addabbo, F. & Goligorsky, M. S. Urine proteomics-prospects for future diagnostics. Acta Physiol. Hung. 94, 133-141 (2007).
72. Soulez, M. et al. The perlecan fragment LG3 is a novel regulator of obliterative remodeling associated with allograft vascular rejection. Circ. Res. 110, 94-104 (2012).
73. Pilon, E. A. et al. The perlecan fragment LG3 regulates homing of mesenchymal stem cells and neointima formation during vascular rejection. Am. J. Transplant. 15, 1205-1218 (2015).
74. Iwata, T. et al. Anti-type V collagen humoral immunity in lung transplant primary graft dysfunction. J. Immunol. 181, 5738-5747 (2008).
75. Yoshida, S. et al. Anti-type V collagen lymphocytes that express IL-17 and IL-23 induce rejection pathology in fresh and well-healed lung transplants. Am. J. Transplant. 6, 724-735 (2006).
76. Tiriveedhi, V. et al. A shift in the collagen V antigenic epitope leads to T helper phenotype switch and immune response to self-antigen leading to chronic lung allograft rejection. Clin. Exp. Immunol. 167, 158-168 (2012).
77. Burlingham, W. J. et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J. Clin. Invest. 117, 3498-3506 (2007).
78. Hachem, R. R. et al. Antibodies to K-alpha 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am. J. Transplant. 12, 2164-2171 (2012).
79. Tiriveedhi, V. et al. Pre-transplant antibodies to Kalpha1 tubulin and collagen-V in lung transplantation: clinical correlations. J. Heart Lung Transplant. 32, 807-814 (2013).
80. Angaswamy, N. et al. Immune responses to collagen-IV and fibronectin in renal transplant recipients with transplant glomerulopathy. Am. J. Transplant. 14, 685-693 (2014).
81. Nath, D. S. et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-α1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 91, 1036-1043 (2011).
82. Braun, R. K. et al. Transfer of tolerance to collagen type V suppresses T-helper-cell-17 lymphocyte-mediated acute lung transplant rejection. Transplantation 88, 1341-1348 (2009).
83. Fan, L. et al. Neutralizing IL-17 prevents obliterative bronchiolitis in murine orthotopic lung transplantation. Am. J. Transplant. 11, 911-922 (2011).
84. Yin, X. T., Zobell, S., Jarosz, J. G. & Stuart, P. M. Anti-IL-17 therapy restricts and reverses late-term corneal allorejection. J. Immunol. 194, 4029-4038 (2015).
85. Basha, H. I. et al. Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by anti-MHC I antibodies. Transplantation 95, 293-300 (2013).
86. Rosen, A. & Casciola-Rosen, L. Autoantigens as substrates for apoptotic proteases: implications for the pathogenesis of systemic autoimmune disease. Cell Death Differ. 6, 6-12 (1999).
87. Bluestone, J. A., Bour-Jordan, H., Cheng, M. & Anderson, M. T cells in the control of organ-specific autoimmunity. J. Clin. Invest. 125, 2250-2260 (2015).
88. Jang, H. R. & Rabb, H. Immune cells in experimental acute kidney injury. Nat. Rev. Nephrol. 11, 88-101 (2015).
89. Zhai, Y., Petrowsky, H., Hong, J. C., Busuttil, R. W. & Kupiec-Weglinski, J. W. Ischaemia-reperfusion injury in liver transplantation-from bench to bedside. Nat. Rev. Gastroenterol. Hepatol. 10, 79-89 (2013).
90. Methe, H., Zimmer, E., Grimm, C., Nabauer, M. & Koglin, J. Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation. Transplantation 78, 1324-1331 (2004).
91. Stribos, E. G. et al. Renal expression of Toll-like receptor 2 and 4: dynamics in human allograft injury and comparison to rodents. Mol. Immunol. 64, 82-89 (2015).
92. Chen, J. et al. Toll-like receptor 4 regulates early endothelial activation during ischemic acute kidney injury. Kidney Int. 79, 288-299 (2011).
93. Kruger, B. et al. Donor Toll-like receptor 4 contributes to ischemia and reperfusion injury following human kidney transplantation. Proc. Natl Acad. Sci. USA 106, 3390-3395 (2009).
94. Tanaka, M. et al. Progression of alloresponse and tissue-specific immunity during graft coronary artery disease. Am. J. Transplant. 5, 1286-1296 (2005).
95. Rose, M. L. Role of anti-vimentin antibodies in allograft rejection. Hum. Immunol. 74, 1459-1462 (2013).
96. Suzuki, H. et al. Role of complement activation in obliterative bronchiolitis post-lung transplantation. J. Immunol. 191, 4431-4439 (2013).
97. Carroll, M. C. The complement system in regulation of adaptive immunity. Nat. Immunol. 5, 981-986 (2004).
98. Dempsey, P. W., Allison, M. E., Akkaraju, S., Goodnow, C. C. & Fearon, D. T. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 271, 348-350 (1996).
99. Marsh, J. E. et al. The allogeneic T and B cell response is strongly dependent on complement components C3 and C4. Transplantation 72, 1310-1318 (2001).
100. Sheen, J. H. & Heeger, P. S. Effects of complement activation on allograft injury. Curr. Opin. Organ Transplant. 20, 468-475 (2015).
101. Sayegh, M. H. & Turka, L. A. The role of T-cell costimulatory activation pathways in transplant rejection. N. Engl. J. Med. 338, 1813-1821 (1998).
102. Valujskikh, A., Lantz, O., Celli, S., Matzinger, P. & Heeger, P. S. Cross-primed CD8+ T cells mediate graft rejection via a distinct effector pathway. Nat. Immunol. 3, 844-851 (2002).
103. Reed, E. F., Tugulea, S. L. & Suciu-Foca, N. Influence of HLA class I and class II antigens on the peripheral T-cell receptor repertoire. Hum. Immunol. 40, 111-122 (1994).
104. Fangmann, J., Dalchau, R. & Fabre, J. W. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides. J. Exp. Med. 175, 1521-1529 (1992).
105. Hanvesakul, R. et al. Indirect recognition of T-cell epitopes derived from the α3 and transmembrane domain of HLA-A2. Am. J. Transplant. 7, 1148-1157 (2007).
106. Vella, J. P. et al. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Transplantation 67, 1523-1532 (1999).
107. Valujskikh, A., Fedoseyeva, E., Benichou, G. & Heeger, P. S. Development of autoimmunity after skin graft rejection via an indirect alloresponse. Transplantation 73, 1130-1137 (2002).
108. Macdonald, W. A. et al. T cell allorecognition via molecular mimicry. Immunity 31, 897-908 (2009).
109. Fukami, N. et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J. Immunol. 182, 309-318 (2009).
110. Saini, D. et al. Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. J. Heart Lung Transplant. 30, 624-631 (2011).
111. Subramanian, V. et al. Immune response to tissue-restricted self-antigens induces airway inflammation and fibrosis following murine lung transplantation. Am. J. Transplant. 14, 2359-2366 (2014).
112. Keller, M. R. et al. Epitope analysis of the collagen type V-specific T cell response in lung transplantation reveals an HLA-DRB1∗15 bias in both recipient and donor. PLoS ONE 8, e79601 (2013).
113. Lehmann, P. V., Forsthuber, T., Miller, A. & Sercarz, E. E. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358, 155-157 (1992).
114. Liu, Z. et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J. Clin. Invest. 98, 1150-1157 (1996).
115. Pallet, N., Dieude, M., Cailhier, J. & Hebert, M. The molecular legacy of apoptosis in transplantation. Am. J. Transplant. 12, 1378-1384 (2012).
116. Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14, 195-208 (2014).
117. Montecalvo, A. et al. Exosomes as a short-range mechanism to spread alloantigen between dendritic cells during T cell allorecognition. J. Immunol. 180, 3081-3090 (2008).
118. Peche, H., Heslan, M., Usal, C., Amigorena, S. & Cuturi, M. C. Presentation of donor major histocompatibility complex antigens by bone marrow dendritic cell-derived exosomes modulates allograft rejection. Transplantation 76, 1503-1510 (2003).
119. Segura, E. et al. ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood 106, 216-223 (2005).
120. Thery, C. et al. Indirect activation of naive CD4+ T cells by dendritic cell-derived exosomes. Nat. Immunol. 3, 1156-1162 (2002).
121. Muntasell, A., Berger, A. C. & Roche, P. A. T cell-induced secretion of MHC class II-peptide complexes on B cell exosomes. EMBO J. 26, 4263-4272 (2007).
122. Nolte-'t Hoen, E. N., Buschow, S. I., Anderton, S. M., Stoorvogel, W. & Wauben, M. H. Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. Blood 113, 1977-1981 (2009).
123. Dieude, M. et al. The 20S proteasome core, active within apoptotic exosome-like vesicles, induces autoantibody production and accelerates rejection. Sci. Transl Med. 7, 318ra200 (2015).
124. Mitsdoerffer, M. et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl Acad. Sci. USA 107, 14292-14297 (2010).
125. Yao, Z. et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3, 811-821 (1995).
126. Rao, D. A. et al. Interleukin (IL)-1 promotes allogeneic T cell intimal infiltration and IL-17 production in a model of human artery rejection. J. Exp. Med. 205, 3145-3158 (2008).
127. Gorbacheva, V., Fan, R., Li, X. & Valujskikh, A. Interleukin-17 promotes early allograft inflammation. Am. J. Pathol. 177, 1265-1273 (2010).
128. Cheng, J. et al. Ectopic B-cell clusters that infiltrate transplanted human kidneys are clonal. Proc. Natl Acad. Sci. USA 108, 5560-5565 (2011).
129. Kerjaschki, D. et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J. Am. Soc. Nephrol. 15, 603-612 (2004).
130. Thaunat, O. et al. Chronic rejection triggers the development of an aggressive intragraft immune response through recapitulation of lymphoid organogenesis. J. Immunol. 185, 717-728 (2010).
131. Thaunat, O. et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc. Natl Acad. Sci. USA 102, 14723-14728 (2005).
132. Sato, M. et al. The role of intrapulmonary de novo lymphoid tissue in obliterative bronchiolitis after lung transplantation. J. Immunol. 182, 7307-7316 (2009).
133. Huibers, M. M. et al. The composition of ectopic lymphoid structures suggests involvement of a local immune response in cardiac allograft vasculopathy. J. Heart Lung Transplant. 34, 734-745 (2015).
134. Aloisi, F. & Pujol-Borrell, R. Lymphoid neogenesis in chronic inflammatory diseases. Nat. Rev. Immunol. 6, 205-217 (2006).
135. Hsu, H. C. et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat. Immunol. 9, 166-175 (2008).
136. Rangel-Moreno, J. et al. The development of inducible bronchus-associated lymphoid tissue depends on IL-17. Nat. Immunol. 12, 639-646 (2011).
137. Patakas, A. et al. Th17 effector cells support B cell responses outside of germinal centres. PLoS ONE 7, e49715 (2012).
138. Szodoray, P., Jellestad, S., Teague, M. O. & Jonsson, R. Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjogren's syndrome. Lab Invest. 83, 357-365 (2003).
139. Thaunat, O. et al. A stepwise breakdown of B-cell tolerance occurs within renal allografts during chronic rejection. Kidney Int. 81, 207-219 (2012).
140. Iyer, H. S., Jackson, A. M., Zachary, A. A. & Montgomery, R. A. Transplanting the highly sensitized patient: trials and tribulations. Curr. Opin. Nephrol. Hypertens. 22, 681-688 (2013).
141. Lefaucheur, C. et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am. J. Transplant. 9, 1099-1107 (2009).
142. Jordan, S. C., Toyoda, M., Kahwaji, J. & Vo, A. A. Clinical aspects of intravenous immunoglobulin use in solid organ transplant recipients. Am. J. Transplant. 11, 196-202 (2011).
143. Morrow, W. R. et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93, 319-324 (2012).
144. Woodle, E. S. et al. Prospective iterative trial of proteasome inhibitor-based desensitization. Am. J. Transplant. 15, 101-118 (2015).
145. Fan, J. et al. Eculizumab salvage therapy for antibody-mediated rejection in a desensitization-resistant intestinal re-transplant patient. Am. J. Transplant. 15, 1995-2000 (2015).
146. Cornell, L. D., Schinstock, C. A., Gandhi, M. J., Kremers, W. K. & Stegall, M. D. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am. J. Transplant. 15, 1293-1302 (2015).
147. Vo, A. A. et al. A phase I/II Trial of the interleukin-6 receptor specific humanized monoclonal (tocilizumab) + intravenous immunoglobulin in difficult to desensitize patients. Transplantation 99, 2356-2363 (2015).
148. Sarma, N. J. et al. Modulation of immune responses following solid organ transplantation by microRNA. Exp. Mol. Pathol. 93, 378-385 (2012).
149. Xu, Z. et al. De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II. J. Immunol. 194, 6133-6143 (2015).
150. Xu, Z. et al. Dysregulated microRNA Expression and chronic lung allograft rejection in recipients with antibodies to donor HLA. Am. J. Transplant. 15, 1933-1947 (2015).
151. Sutherland, S. M. et al. Protein microarrays identify antibodies to protein kinase Czeta that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney Int. 76, 1277-1283 (2009).
152. Hagedorn, P. H. et al. Integrative analysis correlates donor transcripts to recipient autoantibodies in primary graft dysfunction after lung transplantation. Immunology 132, 394-400 (2011).